Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 4/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPA3 | P15088 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533621 | 0.86 | CPA1 (0.70) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL7378715 | 0.85 | CYP1A2 (0.65) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL10824132 | 0.84 | CPA1 (0.68) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL9029155 | 0.84 | CPA1 (0.72) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL7436701 | 0.83 | CYP1A2 (0.57) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL7436695 | 0.83 | CYP1A2 (0.57) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL31344386 | 0.82 | CYP1A2 (0.52) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL4619838 | 0.82 | CYP1A2 (0.52) | CPA1CPB1CPA3CPB2CYP1A2 | |
| SCHEMBL14672759 | 0.80 | CYP2C19 (0.44) | ALDH1A1MEN1KMT2ACYP2C19 | |
| SCHEMBL11529738 | 0.80 | CYP1A2 (0.59) | CPA1CPA3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150311-A1 | COMPOSITIONS AND METHODS FOR INHIBITING IDO1 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150311-A1 | COMPOSITIONS AND METHODS FOR INHIBITING IDO1 | IDO1, IDO2, PYGM | CPA1 542/4885CPB1 932/4885CPA3 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.